Loading company…
Yoda develops drugs for neurological and psychiatric conditions.
Founded in 2019, Yoda is a pharmaceutical company developing drugs for neurological and psychiatric diseases. Its targets include schizophrenia, Alzheimer's disease, Parkinson's disease, autism, ischemic stroke, and traumatic brain disease. The company received FDA orphan drug designation for multiple system atrophy in 2022 and raised over TWD 350 million in series A funding in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in